EQ · Equillium Inc. Common Stock
View on chartInsiders & Stakes
| Connelly Stephen Chief Scientific Officer | ▼ Sell | Open Market | 762,025 Shares held | 6/5/2026 | View profile |
| Zedelmayer Christine Sr. Vice President and COO | ▼ Sell | Open Market | 62,586 Shares held | 6/5/2026 | View profile |
| Rothman Joel Chief Development Officer | ▲ Buy | Grant | 58,150 Shares held | 12/8/2023 | View profile |
| Keyes Jason A Chief Financial Officer | ▼ Sell | Open Market | 37,720 Shares held | 1/23/2025 | View profile |
| Tom Penny Principal Accounting Officer | ▼ Sell | Open Market | 0 Shares held | 5/28/2026 | View profile |
Transaction History
| Zedelmayer Christine | ▼ Sell | Open Market | 14,584 | $43K | 6/5/2026 |
| Connelly Stephen | ▼ Sell | Open Market | 30,975 | $91K | 6/5/2026 |
| Zedelmayer Christine | ▲ Buy | Option Exercise | 14,584 | $11K | 6/5/2026 |
| Connelly Stephen | ▼ Sell | Open Market | 200,000 | $633K | 6/4/2026 |
| Tom Penny | ▲ Buy | Option Exercise | 65,000 | $51K | 5/28/2026 |
| Tom Penny | ▼ Sell | Open Market | 65,000 | $192K | 5/28/2026 |
| Zedelmayer Christine | ▲ Buy | Option Exercise | 7,292 | $5K | 5/28/2026 |
| Zedelmayer Christine | ▼ Sell | Open Market | 55,604 | $150K | 5/28/2026 |
| Zedelmayer Christine | ▲ Buy | Option Exercise | 48,512 | $37K | 5/28/2026 |
| Zedelmayer Christine | ▼ Sell | Open Market | 200 | $542 | 5/28/2026 |
| Zedelmayer Christine | ▲ Buy | Option Exercise | 14,583 | $11K | 5/28/2026 |
| Zedelmayer Christine | ▲ Buy | Option Exercise | 15,625 | $12K | 5/28/2026 |
| Zedelmayer Christine | ▼ Sell | Open Market | 30,208 | $90K | 5/28/2026 |
| Zedelmayer Christine | ▼ Sell | Open Market | 9,821 | $27K | 5/27/2026 |
| Zedelmayer Christine | ▲ Buy | Option Exercise | 9,821 | $8K | 5/27/2026 |
| Zedelmayer Christine | ▲ Buy | Option Exercise | 120,312 | $94K | 3/13/2026 |
| Zedelmayer Christine | ▼ Sell | Open Market | 120,312 | $301K | 3/13/2026 |
| Zedelmayer Christine | ▲ Buy | Option Exercise | 35,695 | $28K | 3/9/2026 |
| Zedelmayer Christine | ▲ Buy | Option Exercise | 41,666 | $33K | 3/9/2026 |
| Zedelmayer Christine | ▲ Buy | Option Exercise | 75,000 | $59K | 3/9/2026 |
| Zedelmayer Christine | ▼ Sell | Open Market | 181,219 | $362K | 3/9/2026 |
| Zedelmayer Christine | ▲ Buy | Option Exercise | 109,375 | $86K | 2/19/2026 |
| Zedelmayer Christine | ▼ Sell | Open Market | 109,375 | $195K | 2/19/2026 |
| Zedelmayer Christine | ▲ Buy | Option Exercise | 76,562 | $56K | 2/19/2026 |
| Zedelmayer Christine | ▼ Sell | Open Market | 76,562 | $133K | 2/19/2026 |
| Tom Penny | ▼ Sell | Open Market | 6,533 | $8K | 1/8/2026 |
| Zedelmayer Christine | ▼ Sell | Open Market | 100,000 | $150K | 12/23/2025 |
| Zedelmayer Christine | ▲ Buy | Option Exercise | 100,000 | $79K | 12/23/2025 |
| Zedelmayer Christine | ▼ Sell | Open Market | 11,900 | $16K | 12/15/2025 |
| Zedelmayer Christine | ▼ Sell | Open Market | 23,804 | $32K | 12/12/2025 |
| Zedelmayer Christine | ▼ Sell | Open Market | 100 | $98 | 11/25/2025 |
| Zedelmayer Christine | ▼ Sell | Open Market | 7,998 | $8K | 11/25/2025 |
| Keyes Jason A | ▼ Sell | Open Market | 10,000 | $7K | 1/23/2025 |
| Keyes Jason A | ▲ Buy | Grant | 15,000 | $8K | 12/10/2024 |
| Keyes Jason A | ▼ Sell | Open Market | 10,000 | $7K | 11/14/2024 |
| Zedelmayer Christine | ▼ Sell | Open Market | 15,000 | $19K | 10/28/2024 |
| Tom Penny | ▼ Sell | Open Market | 2,835 | $4K | 10/28/2024 |
| Tom Penny | ▼ Sell | Open Market | 683 | $854 | 10/25/2024 |
| Keyes Jason A | ▼ Sell | Open Market | 10,000 | $8K | 9/26/2024 |
| Tom Penny | ▼ Sell | Open Market | 38,806 | $33K | 9/16/2024 |
| Keyes Jason A | ▼ Sell | Open Market | 10,000 | $9K | 7/16/2024 |
| Keyes Jason A | ▲ Buy | Grant | 8,805 | $5K | 12/8/2023 |
| Zedelmayer Christine | ▲ Buy | Grant | 8,804 | $5K | 12/8/2023 |
| Rothman Joel | ▲ Buy | Grant | 8,804 | $5K | 12/8/2023 |
| Keyes Jason A | ▲ Buy | Grant | 15,000 | $8K | 6/9/2023 |
| Rothman Joel | ▲ Buy | Grant | 15,000 | $8K | 6/9/2023 |
| Zedelmayer Christine | ▲ Buy | Grant | 15,000 | $8K | 6/9/2023 |
| Rothman Joel | ▲ Buy | Grant | 3,821 | $5K | 12/9/2022 |
| Keyes Jason A | ▲ Buy | Grant | 4,444 | $5K | 12/9/2022 |
| Keyes Jason A | ▼ Sell | Open Market | 7,000 | $20K | 8/29/2022 |
| Rothman Joel | ▲ Buy | Grant | 6,244 | $12K | 6/10/2022 |
| Zedelmayer Christine | ▲ Buy | Grant | 9,033 | $17K | 6/10/2022 |
| Keyes Jason A | ▼ Sell | Open Market | 5,000 | $13K | 6/6/2022 |
| Keyes Jason A | ▼ Sell | Open Market | 8,000 | $25K | 4/4/2022 |
| Keyes Jason A | ▲ Buy | Grant | 5,585 | $13K | 12/10/2021 |
| Rothman Joel | ▲ Buy | Grant | 1,290 | $3K | 12/10/2021 |
| Keyes Jason A | ▼ Sell | Open Market | 5,000 | $25K | 12/1/2021 |
| Zedelmayer Christine | ▲ Buy | Option Exercise | 8,334 | $20K | 11/16/2021 |
| Zedelmayer Christine | ▼ Sell | Open Market | 4,084 | $22K | 11/16/2021 |
| Zedelmayer Christine | ▲ Buy | Option Exercise | 15,000 | $37K | 11/16/2021 |
| Zedelmayer Christine | ▼ Sell | Open Market | 7,350 | $40K | 11/16/2021 |
| Connelly Stephen | ▲ Buy | Option Exercise | 5,625 | $27K | 10/6/2021 |
| Connelly Stephen | ▼ Sell | Open Market | 5,625 | $39K | 10/6/2021 |
| Connelly Stephen | ▲ Buy | Option Exercise | 2,467 | $7K | 10/6/2021 |
| Connelly Stephen | ▼ Sell | Open Market | 2,467 | $17K | 10/6/2021 |
| Keyes Jason A | ▼ Sell | Open Market | 8,000 | $54K | 9/27/2021 |
AI Market Commentary
AI-generatedAll commentary →Synthesized from recent news and fundamentals/technical data -- not human analyst commentary or trader sentiment.
September 28, 2026
Equillium Targets Q4 Phase I Start for Ulcerative Colitis Drug EQ504
Equillium announced plans to start Phase I trials for its ulcerative colitis drug EQ504 in Q4. This milestone could affect the company’s future revenue if the trial is successful. The announcement comes while the stock trades near its 13‑touch support level at $2.20 and has a low RSI of 30.5.
Equillium Targets Q4 Phase I Start for Ulcerative Colitis Drug EQ504. Equillium announced plans to start Phase I trials for its ulcerative colitis drug EQ504 in Q4. This milestone could affect the company’s future revenue if the trial is successful. The announcement comes while the stock trades near its 13‑touch support level at $2.20 and has a low RSI of 30.5.